Epstein-Barr virus lymphoproliferation after bone marrow transplantation

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Allogeneic bone marrow transplantation (BMT) can lead to secondary complications.
• Lymphoproliferative disorders (LPDs) are a rare but serious post-BMT complication.

Purpose of the Study:

• To investigate the incidence, characteristics, and risk factors of secondary B-cell lymphoproliferative disorders after allogeneic BMT.
• To understand the cellular origin and nature of these post-transplant LPDs.

Main Methods:

• Retrospective review of 15 cases of secondary B-cell LPDs among 2,475 allogeneic BMT recipients.
• Histopathologic analysis, Epstein-Barr virus (EBV) genomic sequencing (Southern blot), and immunoglobulin gene rearrangement studies.
• Analysis of risk factors including graft-versus-host disease (GVHD) and T-cell depletion.

Main Results:

• An actuarial incidence of 0.6% for secondary B-cell LPDs was observed.
• EBV genomic sequences were detected in most evaluated lesions, predominantly originating from donor cells.
• Polyclonal proliferations with subsequent clonal subpopulations were indicated by immunoglobulin analysis.
• Anti-CD3 monoclonal antibody treatment and T-cell depletion were significant risk factors; GVHD contributed, especially with HLA disparity.

Conclusions:

• Secondary B-cell LPDs are a rare but significant complication of allogeneic BMT.
• EBV is frequently involved, and these disorders often arise from donor cells.
• Identifying and mitigating risk factors like GVHD and specific immunosuppressive therapies is crucial for BMT recipients.